Table 2.
AA treatment at baseline (FAS)
| Treatment | SAA (n = 209) |
VSAA (n = 83) |
TH-NSAA (n = 48) |
Total (n = 340) |
|---|---|---|---|---|
| HSCT | 7 (3.3) | 5 (6.0) | 0 | 12 (3.5) |
| IST | 155 (74.2) | 58 (69.9) | 35 (72.9) | 248 (72.9) |
| TCM | 32 (15.3) | 9 (10.8) | 2 (4.2) | 43 (12.6) |
| Supportive care | 204 (97.6) | 83 (100) | 38 (79.2) | 325 (95.6) |
| Androgen | ||||
| monotherapy | 7 (3.3) | 0 | 1 (2.1) | 8 (2.4) |
Data are presented asn (%). Patients may have received more than 1 treatment. AA, anaplastic anemia; FAS, full analysis set; SAA, severe AA; VSAA, very severe AA; TD-NSAA, transfusion-dependent non-severe AA; HSCT, hematopoietic stem-cell transplantation; IST, immunosuppressive therapy; TCM, traditional Chinese medicine.